Transglutaminase 2 (TG2) is a multifunctional enzyme with roles in protein crosslinking, extracellular matrix stabilization, and immune response modulation . Antibodies against TG2 are critical in diagnostic and therapeutic contexts, particularly in autoimmune and fibrotic diseases.
Pathogenic Mechanism: Anti-TG2 antibodies are produced locally in the small intestine during gluten exposure. These IgA/IgG antibodies target TG2-gliadin complexes, forming deposits in the intestinal mucosa before appearing in circulation .
Gluten Dependence: Antibody production requires HLA-DQ2/DQ8-restricted gliadin-specific T cells, which provide activation signals to TG2-specific B cells .
Diagnostic Utility: Serum anti-TG2 antibodies are hallmark biomarkers for celiac disease, with >90% sensitivity and specificity .
Recent efforts focus on inhibiting extracellular TG2 to combat fibrosis:
High-Affinity Antibodies: AB1, DC1, and BB7 antibodies inhibit human TG2 transamidation activity (IC<sub>50</sub> ≈6–7 nM) by targeting the catalytic core (amino acids 313–327) .
Species Specificity: Most antibodies show weak inhibition of rat TG2, limiting preclinical models .
Functional Impact: These antibodies reduce extracellular matrix (ECM) accumulation in human renal fibrosis models .
| Antibody | Target Epitope | IC<sub>50</sub> (nM) | Species Reactivity |
|---|---|---|---|
| AB1 | TG2 core (313–327) | 6.2 | Human-specific |
| DC1 | TG2 core (313–327) | 6.9 | Human-specific |
| BB7 | TG2 core (313–327) | 7.1 | Human-specific |
| Data sourced from |
Commercial antibodies like AF4376 and ab109200 are validated for TG2 detection:
AF4376:
ab109200:
Cancer Prognosis:
Fibrosis: TG2 inhibitors like AB1/DC1/BB7 show promise in reducing ECM deposition .
TGA2.2 is a tobacco bZIP transcription factor that belongs to the TGA family of proteins. It has distinct roles in plant defense responses and development . As a transcription factor, TGA2.2 binds to specific DNA sequences, primarily the TGACG pentamer, which serves as the common TGA dimer binding site . TGA2.2 interacts with the promoter of the salicylic acid-inducible PR-1a gene in Nicotiana tabacum, highlighting its importance in plant defense signaling pathways .
TGA2.2 is a clade II member of the TGA family, which typically exhibits shorter N-termini (approximately 40-50 amino acids) compared to other TGA clades. While most TGA family members can recognize the TGACG pentamer binding site, TGA2.2 has distinct roles in plant defense and development compared to its close relative TGA2.1 . The N-terminus of clade II members, including TGA2.2, shows high disorder probability spanning its entire length, which may contribute to its functional specificity .
Similar to validation protocols used for other antibodies, researchers should:
Test the antibody in Western blot assays using wild-type and TGA2.2 knockout cell lines
Perform immunocytochemistry with appropriate controls including knockout cells
Use immunoprecipitation followed by detection with another antibody
Include negative controls (IgG) in all experiments
The knockout validation approach, as demonstrated with the Transglutaminase 2 antibody, provides the most compelling evidence of specificity .
For optimal Western blot results with TGA2.2 antibodies:
Use PVDF membrane for protein transfer
Apply approximately 0.5 μg/mL antibody concentration (based on similar antibody protocols)
Follow with appropriate HRP-conjugated secondary antibody
Conduct the experiment under reducing conditions
Include proper controls such as knockout cell lines to confirm specificity
TGA2.2 should appear as a band at its expected molecular weight (varies by species but typically 40-45 kDa for TGA proteins).
For ChIP assays targeting TGA2.2:
Use approximately 3g of fresh leaf tissue per sample
Apply 5 μL of antibody for immunoprecipitation
Include purified IgG as a nonspecific antibody control
Quantify DNA in samples via qPCR
Design primers to amplify promoter regions containing TGA elements
Focus on regions with the TGACG pentamer or TGACGTCA palindrome, as these are the primary binding sites for TGA transcription factors
Based on protocols for similar applications:
Prepare cell/tissue lysates under conditions that maintain protein complexes
Use 2.0 μg of antibody pre-coupled to Dynabeads protein G
Include controls: starting material (4%), unbound fraction (4%), and immunoprecipitate
Detect immunoprecipitated TGA2.2 with a second antibody from a different species
Include a Ponceau stain of the blot transfer to verify protein loading
This approach will help identify TGA2.2 interaction partners and verify antibody specificity.
To investigate TGA2.2's function in salicylic acid (SA) signaling:
Perform ChIP assays targeting the PR-1a gene promoter, which contains binding sites for TGA2.2 at the as-1-like element (position -592)
Compare TGA2.2 binding before and after SA treatment
Study co-recruitment of interacting partners like NtWRKY12
Analyze the effect of TGA2.2 knockout/knockdown on SA-inducible gene expression
Conduct transactivation experiments in protoplasts to test TGA2.2's ability to activate reporter genes with TGA binding elements
To map TGA2.2 protein interactions:
Perform co-immunoprecipitation with TGA2.2 antibodies followed by mass spectrometry
Use yeast two-hybrid assays with TGA2.2 as bait
Conduct bimolecular fluorescence complementation (BiFC) to visualize interactions in planta
Consider proximity-dependent biotin identification (BioID) to capture transient interactions
Based on known TGA interactions, look specifically for interactions with WRKY transcription factors, NPR proteins, CYCLIN-DEPENDENT KINASE 8, and ROXY glutaredoxins .
| Structural Feature | Implications for Antibody Development | Recommendation |
|---|---|---|
| bZIP domain | Highly conserved across TGA family | Avoid targeting for specific detection |
| N-terminal region | Short (40-50aa) and highly disordered | Challenging target but offers specificity |
| C-terminal region | More structured | Better for antibody stability but less specific |
| Dimerization domains | May be inaccessible in complexes | Target epitopes that remain accessible |
The intrinsic disorder patterns of TGA N-terminal regions appear to be clade-dependent, with clade II members (including TGA2.2) exhibiting high disorder probability throughout their short N-termini .
TGA transcription factors can form homodimers, heterodimers, and higher-order complexes . To differentiate between these forms:
Use sequential ChIP (Re-ChIP) with antibodies against different TGA family members
Perform size exclusion chromatography followed by Western blotting
Apply native gel electrophoresis to preserve protein complexes
Consider chemical crosslinking to stabilize complexes before analysis
Use techniques like FRET-FLIM to study interactions in living cells
The oligomerization properties of TGA2 depend on the region spanning its N-terminus and bZIP domain .
Several factors influence TGA2.2 DNA binding that are important for ChIP experimental design:
The TGACG pentamer is the minimal binding site, but the TGACGTCA palindrome provides stronger binding
Ca²⁺/calmodulin interactions can enhance TGA binding to DNA elements
Post-translational modifications may affect DNA binding affinity
Interaction with cofactors like ROXY glutaredoxins modulates binding
The local DNA structure beyond sequence can affect binding specificity
When designing ChIP-qPCR primers, consider these factors and target regions with known or predicted TGA binding sites.
TGA transcription factors undergo various post-translational modifications that can affect both their function and antibody recognition:
Phosphorylation may alter protein conformation and DNA-binding activity
Nitrosylation can modify TGA activity in response to stress
SUMOylation may affect nuclear localization and protein stability
Redox modifications through glutaredoxin interactions influence activity
When developing or using TGA2.2 antibodies, consider whether your antibody target region contains modification sites, as these may mask epitopes under certain conditions .
To study calcium regulation of TGA2.2:
Perform DNA binding assays with and without Ca²⁺/calmodulin
Use calmodulin-binding domain mutants to assess functional significance
Conduct calcium ionophore treatments before ChIP or immunoprecipitation
Test for direct interaction between TGA2.2 and calmodulin using pull-down assays
Several TGAs have been identified as calmodulin (CaM) interactors, and the CaM/Ca²⁺ complex enhances TGA3 binding to TGACG elements both in vivo and in vitro .
| Plant Species | TGA2.2 Homologs | Sequence Identity | Predicted Cross-reactivity |
|---|---|---|---|
| Tobacco (N. tabacum) | TGA2.2, TGA2.1 | 100%, ~85% | High, Moderate |
| Arabidopsis | AtTGA2, AtTGA5, AtTGA6 | ~60-70% | Low-Moderate |
| Other Solanaceae | Various TGA2-like | ~70-90% | Moderate |
| Monocots | TGA-like | ~40-50% | Very low |
Antibodies raised against specific epitopes should be tested for cross-reactivity with related TGA proteins, especially when working with different plant species .
For studying TGA2.2 in non-model plants:
Use antibodies validated in model systems to identify and characterize homologs
Apply virus-induced gene silencing (VIGS) to knock down TGA2.2 expression
Develop transient expression systems using Agrobacterium infiltration
Implement heterologous expression in yeast or Arabidopsis to test functionality
Use CRISPR/Cas systems adapted for plant species without established transformation protocols
Cross-species complementation experiments can help determine functional conservation of TGA2.2 across different plant lineages.